Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-30T01:35:22.135Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-1696 – Metabolic Outocomes Among Schizophrenia and Bipolar Disorder Patients

Published online by Cambridge University Press:  15 April 2020

A. Ventriglio ,
A. Gentile ,
R.J. Baldessarini ,
S. Martone ,
G. Vitrani ,
A. La Marca  and
A. Bellomo
A. Ventriglio
Affiliation:
University of Foggia Department of Clinical and Experimental Medicine Section of Psychiatry Foggia Italy, University of Foggia, foggia, Italy
A. Gentile
Affiliation:
University of Foggia Department of Clinical and Experimental Medicine Section of Psychiatry Foggia Italy, University of Foggia, foggia, Italy
R.J. Baldessarini
Affiliation:
Department of Psychiatry Harvard Medical School International Consortium for Bipolar and Psychotic Disorders Research McLean Hospital Belmont Massachusetts USA., Harvard Medical School, Boston, USA
S. Martone
Affiliation:
University of Foggia Department of Clinical and Experimental Medicine Section of Psychiatry Foggia Italy, University of Foggia, foggia, Italy
G. Vitrani
Affiliation:
University of Foggia Department of Clinical and Experimental Medicine Section of Psychiatry Foggia Italy, University of Foggia, foggia, Italy
A. La Marca
Affiliation:
University of Foggia Department of Clinical and Experimental Medicine Section of Psychiatry Foggia Italy, University of Foggia, foggia, Italy
A. Bellomo
Affiliation:
University of Foggia Department of Clinical and Experimental Medicine Section of Psychiatry Foggia Italy, University of Foggia, foggia, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Purpose

As weight-gain and metabolic abnormalities during treatment with psychotropic drugs are of great concern, we evaluated effects of psychoeducation and medical monitoring on metabolic changes among severely mentally ill patients.

Materials and Methods

During repeated, systematized psychoeducation about physical health among 66 consecutive patients diagnosed with DSM-IV schizophrenia (SZ; n=33) or type-I bipolar disorder (BD; n=33), we evaluated (at intake, 1, 2, 3, and 6 months) clinical psychiatric status, treatments and doses, rated drugs- attitude of patients, and recorded physiological parameters.

Results

At intake, BD vs. SZ patients were receiving 3–7-times more psychotropic medication, with correspondingly higher initial body-mass index (BMI: 29.1 vs. 25.6 kg/m2), 12-times more obesity, and significantly higher serum lipid concentrations. During 6-month follow-up, ratings of drugs- attitude of patients improved, polytherapy decreased in BD, and BMI decreased slightly, as serum lipid concentrations declined continuously (e.g., total cholesterol+triglycerides: BD by 3.21 > SZ by 1.75%/month). Declining lipid levels were associated with: [a] older age, [b] BD diagnosis, [c] being unemployed, [d] higher antipsychotic dose, [e] lower initial BPRS scores (all p≤0.001).

Type
P38 - Others
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.